Skip to main content
Premium Trial:

Request an Annual Quote

Schott Extends License to Accelr8's Microarray Slide-Coating Technology

NEW YORK (GenomeWeb News) — Accelr8 today said it has extended a
licensing agreement with Schott  Nexterion that allows Schott to use its surface-coating chemistry to make and market microarray slides.
 
Under the new two-year agreement, Schott will have access to a version of Accelr8’s OptiChem product to produce its Slide HS microarraying slides.
 
The OptiChem technology uses a protein to create an even and stable slide surface, according to Accelr8.
 
Financial terms of the agreement were not released.
 
The two companies previously extended a 2004 agreement for another version of OptiChem.

The Scan

Expanded Genetic Testing Uncovers Hereditary Cancer Risk in Significant Subset of Cancer Patients

In Genome Medicine, researchers found pathogenic or likely pathogenic hereditary cancer risk variants in close to 17 percent of the 17,523 patients profiled with expanded germline genetic testing.

Mitochondrial Replacement Therapy Embryos Appear Largely Normal in Single-Cell 'Omics Analyses

Embryos produced with spindle transfer-based mitochondrial replacement had delayed demethylation, but typical aneuploidy and transcriptome features in a PLOS Biology study.

Cancer Patients Report Quality of Life Benefits for Immune Checkpoint Inhibitors

Immune checkpoint inhibitor immunotherapy was linked in JAMA Network Open to enhanced quality of life compared to other treatment types in cancer patients.

Researchers Compare WGS, Exome Sequencing-Based Mendelian Disease Diagnosis

Investigators find a diagnostic edge for whole-genome sequencing, while highlighting the cost advantages and improving diagnostic rate of exome sequencing in EJHG.